Hostname: page-component-cb9f654ff-9b74x Total loading time: 0 Render date: 2025-09-09T07:14:14.654Z Has data issue: false hasContentIssue false
  • English
  • Français

Susceptibility of healthcare personnel with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) hybrid immunity to XBB lineage reinfection

Published online by Cambridge University Press:  20 February 2024

Karissa A. Whiting Open the ORCID record for Karissa A. Whiting [Opens in a new window] ,
Rebecca Guest Open the ORCID record for Rebecca Guest [Opens in a new window] ,
Venkatraman E. Seshan  and
Mini Kamboj
Karissa A. Whiting*
Affiliation:
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
Rebecca Guest
Affiliation:
Employee Health, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Venkatraman E. Seshan
Affiliation:
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
Mini Kamboj
Affiliation:
Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Infection Control, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, New York, New York
*
Corresponding author: Karissa A. Whiting; Email: whitingk@mskcc.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Among 8,678 vaccinated healthcare personnel (HCP) with previous coronavirus disease 2019 (COVID-19), by August 28, 2023, 909 (10%) had an infection of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron XBB variant. Reinfection risk was comparable irrespective of previous infection type except for the omicron BQ.1 variant. Bivalent vaccination had a protective effect. COVID-19 vaccines remain vital to protect HCP, including those with hybrid immunity.

Information

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 45 , Issue 6 , June 2024 , pp. 781 - 784
Check for updates
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Richterman, A, Behrman, A, Brennan, PJ, O’Donnell, JA, Snider, CK, Chaiyachati, KH. Durability of severe acute respiratory syndrome coronavirus 2 messenger RNA booster vaccine protection against omicron among healthcare workers with a vaccine mandate. Clin Infect Dis 2023;76:e319–e326.CrossRefGoogle ScholarPubMed
Ma, KC, Shirk, P, Lambrou, AS, et al. Genomic surveillance for SARS-CoV-2 variants: circulation of omicron lineages—United States, January 2022–May 2023. Morb Mortal Wkly Rep 2023;72:651–656.CrossRefGoogle ScholarPubMed
Tan, CY, Chiew, CJ, Pang, D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. Lancet Infect Dis 2023;23:799–805.CrossRefGoogle Scholar
Moderna clinical trial data confirm its updated COVID-19 vaccine generates robust immune response in humans against widely circulating variants. Moderna website. https://investors.modernatx.com/news/news-details/2023/Moderna-Clinical-Trial-Data-Confirm-Its-Updated-COVID-19-Vaccine-Generates-Robust-Immune-Response-in-Humans-Against-Widely-Circulating-Variants/default.aspx. Published August 17, 2023. Accessed August 18, 2023, 2023.Google Scholar
Sheward, DJ, Yang, Y, Westerberg, M, et al. Sensitivity of BA.2.86 to prevailing neutralising antibody responses. bioRxiv 2023. doi: 10.1101/2023.09.02.556033.Google ScholarPubMed
Bell, J, Meng, L, Barbre, K, et al. Influenza and up-to-date COVID-19 vaccination coverage among healthcare personnel—National Healthcare Safety Network, United States, 2022–23 influenza season. Morb Mortal Wkly Rep 2023;72:1237–1243.CrossRefGoogle Scholar
Robilotti, EV, Whiting, K, Lucca, A, et al. Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the omicron surge, December 2021 to January 2022. Clin Microbiol Infect 2022;28: 1624–1628.CrossRefGoogle ScholarPubMed
Health. N. Coronavirus Data. GitHub. NYC Health. Coronavirus data. GitHub website. https://github.com/nychealth/coronavirus-data. Accessed December 15, 2023.Google Scholar
Stone, TD, Lee, C, Bannon, J, Vu, TT, Hirschhorn, LR, Wilkins, JT, Evans, CT. Intentions for uptake of the coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers. Infect Control Hosp Epidemiol 2023;44:690–692.CrossRefGoogle ScholarPubMed
Jones, JM, Manrique, IM, Stone, MS, et al. Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status—United States, April 2021–September 2022. Morbid Mortal Wkly Rep 2023;72:601–605.CrossRefGoogle ScholarPubMed
Supplementary material: File

Whiting et al. supplementary material

Whiting et al. supplementary material
Download Whiting et al. supplementary material(File)
File 388.6 KB